Results 141 to 150 of about 163,060 (262)

Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia

open access: yesBlood Cancer Journal
Hiroki Akiyama   +17 more
doaj   +1 more source

Translational Macrophage Mechano‐Immunotherapy for Next‐Generation Implantable Biomaterials

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review explores how macrophage mechanosensing drives inflammation, fibrosis and foreign body responses to implanted biomaterials. It examines emerging pharmacological strategies to modulate mechanotransduction, alongside biomaterial platforms for localised drug delivery, clinical translation, regulatory considerations and standardised testing ...
Xueying Xu, Ian L. Chin, Richard P. Tan
wiley   +1 more source

Modulation of Animal Gut Health by Milk Oligosaccharide

open access: yesAnimal Research and One Health, EarlyView.
This review summarizes the composition and structural characteristics of MOs across different mammalian species, and elucidates their roles and mechanisms in maintaining intestinal homeostasis by regulating gut microbiome and enhancing intestinal chemical, physical and immune barriers.
Ningtao Chen   +7 more
wiley   +1 more source

Menin Inhibitors in Acute Myeloid Leukemia: From Molecular Rationale to Clinical Practice. [PDF]

open access: yesJ Pers Med
Alati C   +8 more
europepmc   +1 more source

RNA‐Binding Proteins Shape Mammalian Retroelement RNA Fate: Lessons From HIV‐1, LINE‐1, and Related Reverse‐Transcribing Elements

open access: yesAnimal Research and One Health, EarlyView.
RNA‐binding proteins (RBPs) and RNA‐associated factors shape retroelement RNA fate by regulating RNA processing, translation, RNP assembly and remodeling, reverse transcription, nuclear trafficking, chromatin engagement, and RNA surveillance. These pathways balance productive retroviral replication or retrotransposon insertion with RNA decay ...
Mingrui Li, Zhangyuan Pan, Yongjuan Guan
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy